Home Cart Sign in  
Chemical Structure| 82854-37-3 Chemical Structure| 82854-37-3

Structure of Echinacoside
CAS No.: 82854-37-3

Chemical Structure| 82854-37-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Echinacoside is a naturally occuring caffeic acid glycoside with antiapoptotic effect.

Synonyms: Kusaginin; trans-Verbascoside; trans-Acteoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Echinacoside

CAS No. :82854-37-3
Formula : C35H46O20
M.W : 786.73
SMILES Code : C[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](OCCC3=CC(O)=C(O)C=C3)O[C@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H]2OC(/C=C/C5=CC(O)=C(O)C=C5)=O)O1
Synonyms :
Kusaginin; trans-Verbascoside; trans-Acteoside
MDL No. :MFCD00075695
InChI Key :FSBUXLDOLNLABB-ISAKITKMSA-N
Pubchem ID :5281771

Safety of Echinacoside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
N9 microglial cells 5–20 μM 24 h To investigate the effect of Echinacoside on LPS-induced N9 microglial cell activation, results showed that Echinacoside reduced the secretion of inflammatory factors and inhibited M1 polarization. PMC9846169
rat pituitary cells 10^-6 M to 10^-5 M 15 and 30 min To evaluate if echinacoside could be an agonist of growth hormone secretagogue receptor (GHSR), it was subjected to examination of the induction of growth hormone secretion from primary rat anterior pituitary cells. The results showed that echinacoside was able to significantly stimulate the secretion of growth hormones from rat pituitary cells, and this stimulation was inhibited by a GHSR inverse agonist. PMC6413234
Hepatic Stellate Cells (HSC-T6) 125, 250, 500 μg/mL 48 h Inhibited HSC proliferation, blocked TGF-β1/smad signaling pathway, reduced mRNA and protein expression of smad2 and smad3, and increased expression of smad7. PMC6273390
Human umbilical vein endothelial cells (HUVECs) 30 µM 24 h Echinacoside inhibited LPS-induced pathological activation and mitochondrial pathway apoptosis of endothelial cells by activating SIRT1 and promoting its expression, inhibiting NOX4 activation, and facilitating NOX4 ubiquitination degradation. PMC10669561
lipoxygenase isolated from rat lung cytosol fraction 296 μM 30 min Ineffective against LOXs in lower concentrations, while higher concentration showed similar inhibition on 8-LOX and 12-LOX (28.7% and 27%, respectively). 15-LOX was more sensitive, and the presence of echinacoside decreased its activity to 47%. PMC6264466
Human SW480 colorectal cancer cells 25, 35, 45, 55, 65, 75, 85, 95 μM 24, 48 h Echinacoside dose-dependently inhibited the growth of SW480 cells, with IC50 values of 55.39 and 35.05 μM for 24 and 48 h, respectively. PMC4519864
Human SW480 colorectal cancer cells 60, 80 μM 10 days Echinacoside dose-dependently inhibited the colony formation of SW480 cells. PMC4519864
Human SW480 colorectal cancer cells 60, 80 μM 24 h Echinacoside induced G1 phase cell cycle arrest in SW480 cells and upregulated the G1/S-CDK blocker CDKN1B (p21). PMC4519864
Human SW480 colorectal cancer cells 60, 80 μM 24 h Echinacoside induced apoptosis in SW480 cells, increasing the levels of active caspase 3 and cleaved PARP proteins. PMC4519864
Human SW480 colorectal cancer cells 60, 80 μM 24 h Echinacoside increased the level of oxidized guanine 8-oxoG in SW480 cells, indicating induction of oxidation in the nucleotide pool and/or DNA molecules. PMC4519864
Human SW480 colorectal cancer cells 60, 80 μM 24 h Echinacoside caused extensive DNA damage in SW480 cells, as evidenced by a significant increase in 53BP1 protein. PMC4519864

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Exercise-induced injury model Oral gavage 100 mg/kg Once daily for 1 week Echinacoside significantly reduced the infiltration rate of natural killer cells (NK cells) in peripheral blood post-exercise and decreased the expression levels of key genes (GZMB, PRF1, FASLG, and CCL4). PMC9523794
C57BL/6 mice Chronic unpredictable mild stress (CUMS) induced depression model Gavage 15 and 60 mg/kg Once daily for 21 days To investigate the effect of Echinacoside on CUMS-induced depressive-like behaviors, results showed that Echinacoside reversed CUMS-induced behavioral changes, reduced levels of inflammatory factors, and increased p-CREB/CREB ratio and BDNF levels in the hippocampus. PMC9846169
C57BL/6 mice Sepsis-induced acute lung injury model Intraperitoneal injection 1 mg/kg, 5 mg/kg, 25 mg/kg Single injection, lasting 24 hours Echinacoside alleviated sepsis-induced acute lung injury through the SIRT1-mediated NOX4-Nrf2 axis, inhibited oxidative stress, and preserved endothelial cell function. PMC10669561

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00065715 Common Cold Phase 3 Completed - United States, Wisconsin ... More >> University of Wisconsin-Madison Department of Family Medicine Madison, Wisconsin, United States, 53706-1490 Less <<
NCT03463018 Generalized Anxiety Disorder Phase 2 Recruiting May 2019 Georgia ... More >> Simon Skechinashvili University Hospital Recruiting Tbilisi, Georgia Contact: Ramiaz Shengelia, PhD MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.27mL

0.25mL

0.13mL

6.36mL

1.27mL

0.64mL

12.71mL

2.54mL

1.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories